Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary ...

Opthea was making preparations for the potential launch of a new eye disease drug onto the market. | A month ago, Opthea was ...

Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

Opthea's Phase 3 COAST trial for wet AMD did not meet its primary endpoint, raising financial concerns as the company faces ...

The Australian biotech could potentially be on the hook for more than $1bn after sozinibercept failed to show impact over ...

The Phase 2b ASPIRE clinical trial of intravitreal UBX1325 involed patients with diabetic macular edema (DME) who had poor ...

Opthea's sozinibercept and Unity's UBX1325 fail to match Regeneron's Eylea in separate eye disease trials; Opthea faces ...